Compare Shell PLC (SHEL) vs Summit Therapeutics Inc (SMMT) Price & Performance

Shell (SHEL) trades at $100.56, up 3.83% today, approaching its 52-week high. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The stock shows bullish technical signals, supported by strong cash flow and a 61.5% analyst buy rating. Key developments include the LNG Canada Phase 2 expansion, doubling export capacity, and new carbon capture deals, highlighting strategic growth in energy transition assets.

Outlook remains positive with valuation metrics like P/E of 11.08 and EV/EBITDA of 4.8 suggesting room for upside toward the $102.53 consensus target. Risks include volatile oil prices and execution challenges in new projects, but robust LNG demand and portfolio optimization provide a solid foundation for investor returns.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.